Sanofi (NASDAQ:SNY) Shares Acquired by Patriot Financial Group Insurance Agency LLC

Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 9.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,025 shares of the company’s stock after purchasing an additional 1,737 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Sanofi were worth $1,212,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the second quarter worth $25,000. Larson Financial Group LLC boosted its holdings in Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after acquiring an additional 500 shares during the last quarter. Northwest Investment Counselors LLC acquired a new position in Sanofi in the third quarter valued at $29,000. Palisade Asset Management LLC acquired a new position in Sanofi in the first quarter valued at $31,000. Finally, Concord Wealth Partners boosted its holdings in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Trading Up 0.0 %

NASDAQ:SNY opened at $54.36 on Tuesday. The business’s 50-day moving average is $56.08 and its two-hundred day moving average is $51.84. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 12 month low of $44.05 and a 12 month high of $58.97. The firm has a market capitalization of $137.96 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 1.55 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period last year, the company posted $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.